Important Safety Information

  • DIFICID® is contraindicated in patients with hypersensitivity to fidaxomicin
View additional ISI

Indications and Usage

  • DIFICID is a macrolide antibacterial drug indicated in adults ≥18 years of age for treatment of Clostridium difficile-associated diarrhea
  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID and other antibacterial drugs, DIFICID should be used only to treat infections that are proven or strongly suspected to be caused by Clostridium difficile

Important Safety Information

  • DIFICID is contraindicated in patients with hypersensitivity to fidaxomicin
  • DIFICID should not be used for systemic infections
  • Acute hypersensitivity reactions (angioedema, dyspnea, pruritus, and rash) have been reported. In the event of a severe reaction, discontinue DIFICID
  • Only use DIFICID for infection proven or strongly suspected to be caused by C. difficile. Prescribing DIFICID in the absence of a proven or strongly suspected C. difficile infection is unlikely to provide benefit to the patient and increases the risk of the development of drug- resistant bacteria
  • The most common adverse reactions reported in clinical trials are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%)

To report SUSPECTED ADVERSE REACTIONS, contact Cubist Pharmaceuticals at 1-877-CUBIST-6 or FDA at (1-800-FDA-1088) or www.fda.gov/medwatch.

Please see full prescribing information for DIFICID.

Intake Form Physician

Welcome to the DIFICID.com healthcare professionals site. The content on this site is intended only for healthcare professionals and is not intended for the general public.